The ESMO/ECC congress (European Society for Medical Oncology/European Cancer Congress) took place in Vienna, Austria, September 25-29. The main topic of the conference was immunotherapies especially in advanced kidney cancer with nivolumab in phase III and in metastatic lung cancer with atezolizumab in phase II. Targeted therapies were also highlighted with cabozantinib proposed in advanced renal cancer or everolimus in differenciated neuroendocrine tumors grade 1 or 2. Furthermore the current challenges remain unchanged: improving patients' care through better selection and finding biomarkers using simple samples (blood or urine). Also early phases and personalized medicine found their place in the different presentations and were highlighted largely bringing new approaches in the treatment of metastatic patients.
Bulletin du cancer. 2016 May 23 [Epub ahead of print]
Clément Bonnet, Guillaume Beinse, Luc Cabel, Delphine Cochereau, Pernelle Lavaud, Pauline Rochefort, Emeline Tabouret, Anthony Turpin, Loic Verlingue, Cécile Vicier, Christophe Massard
AERIO, 149, avenue du Maine, 75014 Paris, France., AERIO, 149, avenue du Maine, 75014 Paris, France., AERIO, 149, avenue du Maine, 75014 Paris, France., AERIO, 149, avenue du Maine, 75014 Paris, France., AERIO, 149, avenue du Maine, 75014 Paris, France., AERIO, 149, avenue du Maine, 75014 Paris, France., AERIO, 149, avenue du Maine, 75014 Paris, France., AERIO, 149, avenue du Maine, 75014 Paris, France., AERIO, 149, avenue du Maine, 75014 Paris, France., AERIO, 149, avenue du Maine, 75014 Paris, France., AERIO, 149, avenue du Maine, 75014 Paris, France; DITEP, Gustave-Roussy, 94805 Villejuif, France. Electronic address: .